Evidence map›Paper›PMID 25403366›Full record

ArticleThe American journal of gastroenterology2014

Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.

Xiaobin Feng, Ruocai Xu, Xilin Du, Kefeng Dou, Xiao Qin, Jun Xu, Weidong Jia, Zhiming Wang, Hongzhi Zhao, Shufa Yang and 3 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in The American journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 12 institutions in 1 country.

Xiaobin FengInstitute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.
Ruocai XuHunan Provincial Tumor Hospital, Changsha, China.
Xilin DuTangdu Hospital of Forth Military Medical University, Xi'an, China.
Kefeng DouXijing Hospital of Forth Military Medical University, Xi'an, China.
Xiao QinThe First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Jun XuThe First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Weidong JiaAnhui Provincial Hospital, Hefei, China.
Zhiming WangXiangya Hospital of Central South University, Changsha, China.
Hongzhi ZhaoXinqiao Hospital of Third Military Medical University, Chongqing, China.
Shufa YangXinjiang Tumor Hospital, Wulumuqi, China.
Chenyang GuoHenan Cancer Hospital, Zhengzhou, China.
Tianqi LiuThe People's Hospital of Guangxi Zhuang Zu Autonomous Region, Nanning, China.
Kuansheng MaInstitute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.
Army Medical University · CNAnhui Provincial Hospital · CNCentral South University · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CNGuangxi Medical University · CNHenan Cancer Hospital · CNHunan Cancer Hospital · CNSouthwest Hospital · CNTang Du Hospital · CNThe People's Hospital of Guangxi Zhuang Autonomous Region · CNTumor Hospital of Xinjiang Medical University · CNXijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe objective of this study was to evaluate the efficacy of combined therapy using Sorafenib and radiofrequency ablation (RFA) with curative intent for all detectable lesions in patients with Barcelona Clinic Liver Cancer (BCLC) Stage 0-B1 hepatocellular carcinoma (HCC).

methodsOne hundred and twenty-eight patients with HCC from 12 centers were enrolled in this retrospective study; 64 patients who received Sorafenib plus RFA (Sorafenib-RFA) were compared with a control group treated with RFA alone. The two patient groups were selected with a predefined criterion and matched in terms of their clinical and tumor characteristics at baseline. The primary end point of the study was the incidence of post-RFA HCC recurrence. Secondary end points were overall survival (OS) and treatment toxicity.

resultsDuring a median follow-up of 134.1 weeks, 49 patients died and 79 survived. The 1-, 2-, and 3-year cumulative incidences of post-RFA recurrence were 40.5%, 62.9%, and 74.5%, respectively, in the Sorafenib-RFA group, and 62.8%, 85.4%, and 92.7%, respectively, in the RFA group. The 1-, 2-, 3-, and 4-year OS rates were 85.6%, 64.0%, 58.7%, and 50.3%, respectively, in the Sorafenib-RFA group, and 80.7%, 47.2%, 30.9%, and 30.9%, respectively, in the RFA group. Thus, the Sorafenib-RFA group exhibited better survival than the RFA alone group.

conclusionsCombined therapy with Sorafenib-RFA was associated with a lower incidence of post-RFA recurrence and better OS than RFA alone in patients with BCLC Stage 0-B1 HCC. Although these findings suggest that Sorafenib and RFA is safe and effective for the treatment of early HCC, prospective and randomized controlled trials are needed to validate them.

Indexed as

AdultAntineoplastic AgentsCarcinoma, HepatocellularCatheter AblationCohort StudiesCombined Modality TherapyDisease-Free SurvivalFemaleHumansLiver NeoplasmsMaleMiddle AgedNeoplasm StagingNiacinamidePhenylurea CompoundsRetrospective StudiesAntineoplastic AgentsNiacinamidePhenylurea CompoundsSorafenib

Identifiers

PMID25403366
OpenAlexW1987073180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.